CLBT has recovered 5% this week to $13.35, but the stock is still down 26% year-to-date — and with Q1 earnings now just 12 days away on May 14, the options market is flashing a more cautious read than the week's price action suggests.
Options positioning has shifted more defensive heading into the print. The put/call ratio is running at 0.30, about 1.4 standard deviations above its 20-day average of 0.23. That's not an extreme reading — the 52-week high is 0.43 — but the directional move this week is clear. The PCR has climbed steadily from around 0.17 in late April to its highest level since February, as traders quietly add more hedging while the price rebounds. The options market is not panicking, but it is not celebrating the bounce either.
Short interest tells a different story, and it deserves a separate look. Bears added roughly 10% to their position over the past week, pushing estimated SI to 2.1% of the free float. That's a meaningful week-on-week jump, yet in absolute terms 2.1% is modest. Borrow conditions confirm there's no aggressive squeeze setup here: cost to borrow has eased 22% over the past month to just 0.34%, and availability remains loose, with only about 5% of the lending pool currently drawn down — well below the 52-week peak of 18%. The week-on-week build in short positions looks more like tactical hedging ahead of earnings than a conviction short thesis.
The Street is uniformly bullish on paper, but the price targets tell the real story. All five covering analysts rate the stock a Buy, and the mean target is around $21.67 — implying over 60% upside from current levels. That gap is a function of where the stock has traded: it's down sharply from the mid-$20s levels where most targets were set. The most recent analyst action, Needham's target cut to $18 back in February following Q4 results, is now three months stale, and no firm has revisited targets since. The bull case centres on platform expansion and the pending Corellium acquisition broadening the offering; bears point to privacy-related perception risks, competitive pressure, and extended enterprise sales cycles. At 23x trailing P/E and 16.7x EV/EBITDA, the valuation is not demanding for a software name if growth holds, but both multiples have drifted lower over the past month as the stock has underperformed.
The earnings history adds context. February's Q4 print saw the stock fall 8.3% on the day and extend losses to -6% over the following five days — a notably negative immediate reaction. The only prior datapoint available showed a +4.4% day-one move but a -3.9% five-day result. On both occasions the stock sold off into the following week. At $13.35, the stock trades closer to the lower end of analyst targets, which gives bears less room to press and bulls a cleaner risk/reward argument — but the consistent post-earnings drift lower remains the pattern to watch heading into May 14.
Close peers TENB and DT both gained around 6% this week, broadly in line with CLBT's recovery. MANH bucked the trend with a slight weekly decline of 1.6%, suggesting the software group's rebound is not uniform. The relative convergence across the peer group means CLBT's earnings reaction on May 14 will likely be driven more by company-specific execution than by sector momentum — making the Q1 ARR trajectory and any updated full-year guidance the two numbers most worth tracking on the day.
See the live data behind this article on ORTEX.
Open CLBT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
